Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells

KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogenic driver with mutations in 30% of non-small cell lung cancer (NSCLC). However, there is no effective clinical drug even though it has been identified as an oncogene for 30 years. In this study, we identified a small molecule i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Chun, Li, Ying, Li, Lan-Lan, Fan, Xing-Xing, Wang, Yu-Wei, Wei, Chun-Li, Liu, Liang, Leung, Elaine Lai-Han, Yao, Xiao-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694459/
https://www.ncbi.nlm.nih.gov/pubmed/29184501
http://dx.doi.org/10.3389/fphar.2017.00823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694459/
https://www.ncbi.nlm.nih.gov/pubmed/29184501
http://dx.doi.org/10.3389/fphar.2017.00823

Ejemplares similares